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Abstract
Background: A preliminary exploratory study shows solid agreement between the results of case reports and
clinical study meta-analyses in mucopolysaccharidosis Type I (MPS-I) adult patients. The aim of the present study is
to confirm previous results in another patient population, suffering from mucopolysaccharidosis Type II (MPS-II).
Methods: A systematic review and meta-analysis of case reports published by April 2018 was conducted for MPS-II
patients treated with enzyme replacement therapy (ERT). The study is reported in accordance with PRISMA and
MOOSE guidelines (PROSPERO database code CRD42018093408). The assessed population and outcomes were the
same as previously analyzed in a meta-analysis of MPS-II clinical studies. The primary endpoint was the percent of
clinical cases showing improvement in efficacy outcome, or no harm in safety outcome after ERT initiation. A
restrictive procedure to aggregate case reports, by selecting standardized and well-defined outcomes, was
proposed. Different sensitivity analyses were able to evaluate the robustness of results.
Results: Every outcome classified as “acceptable evidence group” in our case report meta-analysis had been graded
as “moderate strength of evidence” in the aforementioned meta-analysis of clinical studies. Sensitivity, specificity,
and positive-negative predictive values for results of both meta-analyses reached 100%, and were deemed
equivalent.
Conclusions: Aggregating case reports quantitatively, rather than analyzing them qualitatively, may improve
conclusions in rare diseases and personalized medicine. Additionally, we propose some methods to evaluate
publication bias and heterogeneity of the included studies in a meta-analysis of case reports.
Keywords: Systematic review, Meta-analysis, Case reports, Clinical studies, Mucopolysaccharidosis type II, Enzyme
replacement therapy, Evidence-based medicine
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Background
The low prevalence of rare diseases, the phenotype het-
erogeneity and the long latency period, may prevent
and/or make the possibility of performing randomized
clinical trials (RCTs) and large studies extremely difficult
[1, 2]. Therefore, with these diseases, knowledge of treat-
ment efficacy or any other type of clinical knowledge
must be based only on observational studies, rare disease
registries and case reports [2], where real world data and
evidence play an important role in health care decisions
[3]. However, RCTs are assessed, in evidence-based
medicine as the best corroboration of the efficacy of new
treatments, while case reports show a lower grade level
of evidence [1].
Previous FDA drug approvals with breakthrough status
suggest that sometimes non-controlled studies can pro-
vide the same quality of evidence to demonstrate a posi-
tive risk–benefit ratio as individual RCTs [2, 4].
Accordingly, randomized phase II controlled-trials were
not superior to single-arm phase II trials in predicting
phase III study success [5].
In rare diseases, research based on registries and case
studies is likely the best option, due to lack of patients,
and case reports are often the primary evidence of the
effectiveness of a new therapy or treatment [6]. Due to
prior considerations, an increasing interest in case report
analyses, and combining their results in systematic re-
views, exists [7, 8].
Case report databases are developed as the Consensus-
based Clinical Case Reporting (CARE) guidelines [9]
attempt to homogenize and upgrade the quality of the
information published in case reports; however, there
are still questions about how to aggregate them in ways
that would be most meaningful [8].
A previous systematic review of clinical studies, evalu-
ating the effectiveness of enzyme replacement therapy
(ERT) in adults (≥ 18 years) with mucopolysaccharidosis
Type I (MPS-I), rated the strength of evidence (SOE) for
ERT on each outcome with the Grading of Recommen-
dations Assessment, Development and Evaluation
(GRADE) criteria [10]. Another study showed a good
rate of agreement between SOE and specific outcomes
in a case report meta-analysis and clinical study meta-
analyses [11]. This agreement has not been confirmed in
other patient populations. Furthermore, the mentioned
case report meta-analysis and clinical study meta-
analysis were developed by the same research group.
Our proposal performed a meta-analysis of case re-
ports of MPS-II patients treated with ERT, and com-
pared the degree of evidence assigned to each outcome,
vs. what was assigned in a previous clinical study meta-
analysis, published by an independent research group. In
a population suffering from MPS-II, we sought to con-
firm the impressive rate of agreement seen between case
reports and clinical study meta-analyses in patients with
MPS-I [11].
Methods
Data sources and study selection
A systematic review of case reports published through
April 2018 was conducted for MPS-II patients treated
with ERT. It was carried out on EMBASE, MEDLINE,
The Cochrane Library (Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Tri-
als), Cochrane Methodology Register and Health Tech-
nology Assessment Databases) as well as on the Latin
American and Caribbean Literature on Health Sciences
(LILACS). The search strategy retrieved citations in da-
tabases containing the subject headings: Hunter syn-
drome, enzyme replacement, iduronate 2 sultatase,
idursulfase, case report, case study, and medical record
review. The search terms were adapted and used with
different bibliographic databases (see Additional file 1:
Table S1). An inclusive approach was used for low dis-
ease incidence. We included all-language articles/docu-
ments addressing one or more key questions, associated
interventions and outcomes. Selected abstracts and arti-
cles published in languages other than English were
translated into English by native speakers. Study designs
included case reports and reviews of these case reports,
which were put into narrative form. Prospective and
retrospective studies that aggregated patient data were
not considered, although the individual data of each pa-
tient could be extracted. The same outcomes and popu-
lations analyzed in the meta-analysis of clinical studies,
published by Bradley et al. [12], were evaluated. Bradley
et al. had conducted a systematic review of randomized
controlled trials, nonrandomized trials, observational
studies, registry data, systematic evidence reviews, and
health technology assessments (through December 31st,
2015).
Study subjects were males with enzymatically-confirmed
MPS-II, of any age, phenotype, genotype, stage of progres-
sion, or family history. An intervention of interest was the
intravenous administration of idursulfase.
Quality assessment
The study was prospectively designed to confirm MPS-II
patients, as well as results of agreement, which were ob-
served in the MPS-I population [11]. The current meta-
analysis is reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) and Meta-Analyses and Systematic
Reviews of Observational Studies (MOOSE) guidelines
[13, 14]. The protocol was published in the International
Prospective Register of Systematic Reviews (PROSPERO)
database (Code 42018093408).
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Two investigators (SCM and PMA) entered findings
into a database, independently reviewed citations/ab-
stracts from the database and hand searches, and
selected full relevant articles and documents for data
extraction using preset criteria. Discrepancies were re-
solved through discussion or input from a third re-
viewer (PLJ).
Previous study outcomes
In the meta-analysis of MPS-II clinical studies by Brad-
ley et al. [12], each outcome had been scored with a
SOE grade (high, moderate, low, and insufficient) based
on the results of previous clinical studies [15]. Different
outcomes could be classified based in their evidence
level in two groups: Acceptable (high to moderate SOE
grade) and unacceptable (low to insufficient SOE grade).
Outcomes and SOE assigned were:
Acceptable level of evidence
 Urinary glycosaminoglycans (uGAGs) level (μg/mg
creatinine) reduction -- moderate.
 Liver volume -- moderate.
 Harm: development of antibodies -- moderate.
Unacceptable level of evidence
 Harm: Rate of IRRs (infusion-related reactions) and
SAEs (serious adverse events) -- low.
 6-min walk test in meters (6MWT) -- low.
 Growth: height -- low.
 Pulmonary function (forced vital capacity (FVC%),
normalized for age and sex --low.
 Joint range of motion (JROM) -- insufficient.
 Benefit and harm: physical disability/quality of life
-- insufficient.
 Cardiac function -- insufficient.
 Sleep apnea -- insufficient.
The long-term outcomes were not ranked with SOE [12].
Authors said: “no studies addressed longer-term measur-
able ERT outcomes,” which they classified as “none.”
Primary endpoint
Our meta-analysis of case reports considered the same
outcomes analyzed in Bradley’s study [12]. We also
scored each outcome based only on the results of previ-
ous narrative case reports. We divided the number of
case reports with a modification for a specific outcome
after ERT by the total number of case reports analyzed,
and then measured as a percentage. It is important to
consider that we could define an efficacy outcome as im-
proved in a case report only if: (1) the method of out-
come evaluation was described (Ex: An abdominal
ultrasound to characterize the liver size was performed
prior to the start of treatment, then at 6 months and 15
months), or (2) a quantitative measure was reported in
the clinical case (Ex: urine GAGs declined to 12.17–26.1
mg/mmol creatinine). Only infusion-related reactions
(IRR) that caused ERT dose changes were considered
relevant. This restrictive procedure to define an outcome
as improved (efficacy) or worsened (IRR) was considered
a strong confirmatory method. Given this score, we as-
sumed that the greater the percentage of case reports
showing improvements or impairments (IRRs) for a spe-
cific outcome, the higher the grade of evidence for ERT-
driven outcome modifications.
Secondary endpoint
For secondary endpoints, the improvement in ERT was
weakly defined; we assumed the existence of improve-
ment with the mention of improvement in the case re-
port (weak confirmatory method).
Statistical methods
The primary endpoint was the percentage of case reports
with an outcome modification after ERT, based on a
strong confirmatory method. This percentage was calcu-
lated for each of the 11 outcomes analyzed. Additionally,
we classified these outcomes in two groups (acceptable
or unacceptable evidence), based on the percentage of
case reports. To classify them, we tested the null hypoth-
esis for the percentage of case reports with an outcome
modification lower or equal to 5% (H0). We based our
analysis on a one-sided binomial test. Multiplicity issues,
derived from analyzing 11 outcomes [16] were adjusted
by the step-up Benjamini-Hochberg procedure for a false
discovery rate (FDR) of 10%, although more elaborate
extensions of this method are used to assess the import-
ance of the endpoints analyzed [17]. We classified a spe-
cific outcome as acceptable evidence if its p-value was
equal to or lower than the FDR 10% critical value, which
was calculated by ranking the outcomes from the lowest
to the highest p-value. The FDR critical value is defined
as the rank (r) divided by number of outcomes (nr), and
multiplied by the accepted 10% rate of false discoveries.
Outcomes not achieving this were classified as unaccept-
able evidence.
We evaluated the concordance between outcomes in
the acceptable evidence group, based on the primary
outcome and outcomes classified as high to moderate
SOE in the Bradley meta-analysis [12]. The validity indi-
ces reported were sensitivity, specificity and predictive
values, estimated with 95% confidence intervals (CIs).
The primary analysis was performed in the primary
analysis set, which was considered in all case reports of
MPS-II patients, treated with ERT with reported efficacy
and safety. These case reports were written in narrative
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form (results were not aggregated) and published prior
to the bibliographic search by Bradley et al. [12].
The secondary analysis evaluated concordance be-
tween outcomes in the acceptable evidence group, with
a weak confirmatory assumption, and outcomes classi-
fied as high to moderate SOE in the Bradley meta-
analysis [12]. Validity indices were also reported.
Secondary analysis evaluated the relative agreement
between number of case reports showing a modification
in a specific outcome and the SOE score (1 as insuffi-
cient; 2 as low; 3 as moderate, and 4 as high) reported
from the clinical study meta-analysis. Spearman rank
correlation was used to evaluate relative agreement. Re-
sults were presented in a scatter plot.
Sensitivity analysis was planned in three ways. First,
we compared the measures of validity and relative agree-
ment with strong and weak confirmatory methods in the
primary analysis set. Second, we estimated measures of
validity and relative agreement derived with a strong
confirmatory assumption in three analysis sets:
1) Including all case reports, even those published
after the bibliographic search by Bradley et al. (31
December 2015) [12].
2) Excluding all studies that had been analyzed in the
Bradley study.
3) Excluding all congress communications.
We compared the validity indices based on different
assumptions about the futility boundary (null hypoth-
esis): 5% primary analysis-, 1, 10, 15, and 20%. The ana-
lyses were performed in the primary analysis set.
Results
Database searches through April 13th, 2018 identified
331 citations and 289 unique abstracts. The reference of
all abstracts screened and the reason for exclusion are
reported in the Additional file 2. Out of 125 communi-
cations with a full text review, 38 articles and congress
communications described a total of 56 case reports,
and met inclusion criteria. Finally, 44 single-cases were
considered for the primary set of analysis and 56 single-
cases were analyzed in sensitivity analyses (Fig. 1). The
characteristics of the 56 case reports are described in
Additional file 1: Tables S2 and S3.
Primary endpoint analysis
Table 1 describes the number of case reports that show
a modification in a specific outcome after ERT, as de-
fined by the strong confirmatory criterion, among the
total number of case reports selected in the primary ana-
lysis set. Specific outcomes defined as modified in each
case report are summarized in Additional file 1: Tables
S2 and S3.
The outcomes showing a p-value lower than the FDR
10% critical value were classified in the acceptable evi-
dence group. These outcomes were uGAGs, liver volume
and development of antibodies; they had been also clas-
sified as having moderate quality of evidence by SOE cri-
teria in the previous meta-analysis of clinical studies.
Additionally, all outcomes classified in the unacceptable
evidence group (p-value > FDR 10% critical value) had
been classified as having low to insufficient quality of
evidence by the SOE criteria in the Bradley study [12].
Sensitivity analysis of strong and weak confirmatory
methods
Table 2 describes the number of case reports with a
modification in a specific outcome, after ERT, as defined
by the weak confirmatory method.
The outcomes showing a p-value lower than the FDR
10% critical value were classified in the acceptable evi-
dence group. These outcomes were uGAGs, liver vol-
ume, development of antibodies, 6MWT, and quality of
live. All outcomes having moderate SOE in the previous
meta-analysis were classified as acceptable in our study
(uGAGs, liver volume and development of antibodies).
However, there were two additional outcomes (6MWT
and QoL) classified in our acceptable evidence group
with low and insufficient quality of evidence by the SOE
in the Bradley study [12].
In agreement with the results, outcomes classified on
the strong confirmatory method show a positive predict-
ive value (PPV), negative predictive value (NPV), sensi-
tivity (Se), and specificity (Sp) of 100%, compared to
SOE as the gold standard (Table 3). The weak confirma-
tory method shows lower validity indices (60% PPV,
100% NPV, 100% Se, and 75% Sp) vs. the strong con-
firmatory method (see Additional file 1: Table S4).
Likewise, the relative rate of agreement between the
quantitative evidence score, based on case reports with
ERT-modified outcomes, and the SOE were good (Rho =
0.82, 95%CI: 0.43 to 0.95) when the strong confirmatory
method was used (Fig. 2). Conversely, evaluation of
ERT-modified outcomes in case reports based on the
weak confirmatory method showed a moderate rate of
agreement (Rho = 0.63, 95%CI: 0.044 to 0.89) with the
SOE (see Additional file 1: Figure S1).
Sensitivity analysis based on different analysis sets
The outcomes classification based on the strong con-
firmatory method achieved equivalent results vs. the
SOE classification in the meta-analyses of clinical
studies in all analysis sets [at least 10 among 11 out-
comes equally classified (Accuracy ≥91%)]. In
addition, the ratio of agreement between number of
case reports with improved outcomes and the SOE
score was good (Rho > 80%).
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When we excluded congress communications from
the analysis set, the accuracy between our classification
(based on the strong confirmatory method) and the SOE
classification was reduced to 91%, there was no detection
of the development of antibodies as modified by ERT in
our meta-analysis (Table 4).
Sensitivity analysis based on a different null hypothesis
The best validity indices were observed with the pre-
planned futility boundary (5%, null hypothesis). Specifi-
city and positive predictive values were reduced with
boundaries lower than 5%. Sensitivity and negative pre-
dictive values were reduced with boundaries higher than
5% (see Additional file 1: Table S5).
Discussion
Personalized medicine based on molecular diagnosis has
fragmented complex diseases, such as cancer, into mul-
tiple molecular subtypes, each one representing a rare
disease [18, 19]. This has extended the classification of
rare disease to other illnesses that were not previously
considered as such. Thus, the recent importance of re-
search methods derived from rare diseases [20], the de-
velopment and improvement of rare disease registries
[21] and the recovered interest in case reports for aggre-
gating results in systematic reviews [7].
There are few publications aggregating case report re-
sults in a quantitative manner [22]. There is only one
study comparing the results of a case report meta-
Fig. 1 Flow diagram of case reports of patients with MPS-II published between January 2008 to April 2018
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Table 1 Analysis of number of case reports showing improvement or impairment associated with ERT in a specific outcome, based
on the strong confirmatory method
RANK Outcomes & (SOE score*) Nr. [+] / Total cases p-value** FDR 10% Critical value*** Evidence group****
1 uGAGs (Moderate) 20/44 < 0.0001 0.009 Acceptable
2 Liver V (Moderate) 8/44 0.001 0.018 Acceptable
3 Antibodies (Moderate) 6/44 0.022 0.027 Acceptable
4 6MWT (Low) 4/44 0.177 > 0.036 Unacceptable
4 JROM (Insufficient) 4/44 0.177 > 0.036 Unacceptable
5 Growth height (Low) 3/44 0.379 > 0.045 Unacceptable
6 IRR (Low) 2/44 0.653 > 0.055 Unacceptable
7 Pulmonary function (Low) 1/44 0.895 > 0.064 Unacceptable
8 Cardiac (Insufficient) 0/44 1 > 0.073 Unacceptable
8 QoL (Insufficient) 0/44 1 > 0.073 Unacceptable
8 Sleep apnea (Insufficient) 0/44 1 > 0.073 Unacceptable
Legend:The improvement is defined in accordance with the strong confirmatory method. The impairment was declared when an Infusion Related Reaction (IRR)
caused a change in ERT dose.
6MWT 6-min walk test, FDR False discovery rate (Benjamini-Hochberg procedure), IRR infusion-related reaction, JROM Joint range of motion, Nr. [+] Number of case
reports showing improvement or impairment in IRR with ERT in a specific outcome, QoL Quality of life, SOE Strength of evidence, uGAGs
Urinary glycosaminoglycans.
*The SOE classification has been previously published in Bradley et .al [12]
** The analysis assessed whether the percentage of case reports showing a modification in a specific outcome was statistically higher than 5% (null hypothesis,
H0). The p-value was performed with one-sided binomial test
*** FDR critical value: Outcomes with p-values lower than FDR critical value are considered as modified by ERT (Multiplicity adjustment). The FDR critical value is
calculated ranking the outcomes analyzed from lowest to highest p-value. The rank (r) is divided by number of outcomes and multiplied by the accepted 10%
rate of false discoveries. The lowest rank of tied p-values is used because the critical value computed is lower, and it is more conservative to declare a specific
outcome as modified by ERT. However, the same outcomes were classified as modified by ERT when the highest or mean rank was used for ties
**** The outcomes that showed a p-value lower than the FDR 10% critical value were classified in the acceptable evidence group (shadow rows). The outcomes
that showed a p-value higher than the FDR 10% critical value were classified in an unacceptable evidence group (white rows). In bold: Moderate to high
SOE categories
Table 2 Analysis of number of case reports showing improvement or impairment, associated with ERT in a specific outcome, based
on a weak confirmatory method
RANK Outcomes & (SOE score*) Nr. [+] / Total cases p-value** FDR 10% Critical value*** Evidence group****
1 uGAGs (Moderate) 20/44 < 0.0001 < 0.009 Acceptable
2 6MWT (Low) 15/44 < 0.0001 < 0.027 Acceptable
3 Liver V (Moderate) 13/44 < 0.0001 < 0.027 Acceptable
4 QoL (Insufficient) 8/44 0.014 < 0.036 Acceptable
5 Antibodies (Moderate) 6/44 0.022 < 0.045 Acceptable
6 Growth height (Low) 5/44 0.067 N.S (> 0.055) Unacceptable
6 JROM (Insufficient) 5/44 0.067 N.S (> 0.055) Unacceptable
7 Pulmonary function (Low) 4/44 0.177 N.S (> 0.072) Unacceptable
8 IRR (Low) 2/44 0.653 N.S (> 0.064) Unacceptable
9 Sleep apnea (Insufficient) 1/44 0.895 N.S (> 0.082) Unacceptable
10 Cardiac (Insufficient) 0/44 1 N.S (> 0.091) Unacceptable
Legend:The improvement is defined in accordance with the weak confirmatory method. The impairment was declared when IRR caused a change in ERT dose.
6MWT 6-min walk test, FDR False discovery rate (Benjamini-Hochberg procedure), IRR infusion-related reaction, JROM joint range of motion, Nr. [+] Number of case
reports showing improvement or impairment in IRR associated with ERT in a specific outcome, QoL Quality of life, SOE Strength of evidence, uGAGs
Urinary glycosaminoglycans.
*The SOE classification has been previously published in Bradley et al. [12]
** The analysis assessed whether the percentage of case reports showing a modification in a specific outcome was statistically higher than 5% (null hypothesis,
H0). The p-value was performed with a one-sided binomial test
*** FDR critical value: Outcomes with p-values lower than FDR critical value are considered as modified by ERT (Multiplicity adjustment). The FDR critical value is
calculated by ranking the outcomes analyzed from lowest to highest p-value. The rank (r) is divided by number of outcomes and multiplied by the accepted 10%
rate of false discoveries. The lowest rank of tied p-values was used because the critical value is computed is lower, and is more conservative for a specific
outcome as modified by ERT. However, the same outcomes were classified as modified by ERT when the highest or mean rank was used for ties
**** The outcomes showing a p-value lower than the FDR 10% critical value were classified in acceptable evidence groups (shadow rows). The outcomes showed
a p-value higher than the FDR 10% critical value and were classified in unacceptable evidence groups (white rows). In bold: Moderate to high SOE categories
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analysis and a meta-analysis including RCTs [11]; it
showed that both meta-analyses reach similar conclu-
sions in adult MPS-I.
We selected the Bradley meta-analysis [12] as the gold
standard, because it analyzed the overall MPS-II popula-
tion without an age restriction. Furthermore, it had been
recently published and developed by an independent re-
search group. Along with the Bradley study, the efficacy
and safety of ERT in patients with MPS-II had been ana-
lyzed in three previous meta-analyses: that by da Silva
et al. in 2016 [23], which only selected one phase II/III
trial [24], that by Alegra et al. in 2013 [25], which com-
bined 2 RCTs [24, 26] and 1 open label study with the
same patients of all ages [27], 1 open-label study of
adults [28], and 1 cohort study of children [29], plus the
one by Pérez-López et al. in 2018, which analyzed adult
MPS-II patients (> 16 years) [30].
In agreement with our previous study [11], we pro-
posed a single method to aggregate results from different
case reports. We considered the number of cases,
Table 3 Agreement between the classification of outcomes based on the case report meta-analysis and the SOE classification,
based on the clinical study meta-analysis. Strong confirmatory method
Strength of evidence of clinical study meta-analysis
Number of case reports [+] for the outcome High to moderate Low to insufficient




(False positives = 0)
< 6 [+] of 44 cases (unacceptable evidence group) (False negative = 0) (True negatives = 8)
-6MWT, JROM, Growth, IRR, Pulmonary function, Cardiac, QoL, sleep apnea.
Legend: The 95% confidence interval for the validity index are: positive predictive value: 100% (29 to 100%); negative predictive value: 100% (63 to 100%);
sensibility: 100% (29 to 100%), and specificity: 100% (63 to 100%).
6MWT 6-min walk test, CI Confidence interval, IRR Infusion-related reaction, JROM Joint range of motion, NPV Negative predictive value, PPV Positive predictive
value, QoL Quality of life, Se Sensitivity, Sp Specificity, SOE Strength of evidence, uGAGs Urinary glycosaminoglycans.
Fig. 2 Agreement between the evidence score from the case report meta-analysis and the SOE from the clinical study meta-analysis. Strong
confirmatory method. 6MWT: 6-min walk test; CI: Confidence interval; IRR: Infusion-related reaction; JROM: Joint range of motion; QoL: Quality of
life; Rho: Spearman correlation coefficient; SOE: Strenght of evidence; uGAGs: Urinary glycosaminoglycans
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showing a certain characteristic among the total num-
ber of cases analyzed. This method has the flexibility
of combining outcomes independent of the measure-
ment of the variable; it also allows different ways for
controlling the multiplicity, depending on the rela-
tionship among the outcomes analyzed [17]. Addition-
ally, we could consider the information provided from
aggregated results of case reports as a single observa-
tional study and combine the results with case series,
clinical trials and rare disease registries in a meta-
analysis; or we could simply add the cases of all stud-
ies, as if it was a single study [22]. This allows in-
corporating all available evidence (single case
observations, clinical studies and rare disease regis-
tries) to evaluate a particular research question. As an
example, previous studies in infectious disease have
used this strategy to develop classification tree models
to predict disease outcomes [22].
However, the publication bias and heterogeneity of the
included studies represents two critical aspects that were
not considered in previous case report aggregations [13,
31]. Regarding publication bias, funnel plot tests cannot,
be implemented when aggregating case reports [13]. Pre-
vious publications criticize the use of the safe-false N in
meta-analyses of clinical studies [32]. This index evalu-
ates if a significant result of a meta-analysis can become
significant without considering whether the differences
evaluated are clinically meaningful. This limitation can
be avoided in a case report aggregation by testing if the
percentage of responders is higher than the that of re-
sponders in historical controls (clinically meaningful dif-
ference). In accordance, previous clinical trials have
demonstrated the utility of rare disease registries as his-
torical controls [21].
We have proposed to analyze heterogeneity based on
different sensitivity analysis to evaluate the robustness of
the meta-analysis results. We would consider that an
equivalent approach may be easily developed in further
publications [33]. Accordingly, we have proven the ro-
bustness of our results through a specific strategy:
considering all selected case reports, excluding those
published after the clinical study meta-analysis biblio-
graphic search, and excluding studies analyzed in clinical
study meta-analyses, including excluding congress com-
munications. In all scenarios, our results show good
agreement with the SOE score of clinical study meta-
analyses.
Some authors have underlined the utility of N-of-1 tri-
als to compare the effect of different treatments in only
one patient [34]. These designs can randomize repeated
cycles of treatment challenges (e.g., A-B-A-B) in a single
participant, in which A is the test drug and B is the com-
parison drug. These studies achieve the usual methodo-
logical safeguards of classical clinical trials (controlled,
randomized, and blinded). However, these designs are
not applicable in situations where the disease is not clin-
ically stable or the carry-over effects of treatment cannot
be avoided [35]. Therefore, in some diseases, most of the
available evidence comes from case reports [2]. Methods
to aggregate results of different N-of-1 trials in a meta-
analysis assumed randomized allocation of treatment ex-
posure about study periods [36, 37]. They cannot be ap-
plied to aggregate results of case report narratives or
rare diseases registries.
As we have mentioned, rare disease registries may be
valuable sources of information not only on disease
course but also on treatment outcomes. A global regis-
try, Hunter Outcome Survey (HOS), has been collecting
information on patients with MPS II for over 10 years
[38]. Our results seem to agree with those from the
registry. Based on data from the HOS registry [39], ERT
with idursulfase has a positive effect on uGAGs, and
liver volume, 2 outcomes showed as of acceptable evi-
dence in our analysis by the strong method, and also on
6MWT, which was also categorized in our analysis as ac-
ceptable evidence by the weak method. In addition, data
from the HOS registry showed that 59% of patients
younger than 12 years and 67% of those 12 years or older
were positive for antibodies by week 13 of treatment
[40], in agreement with antibody development being
Table 4 Sensitivity analysis based on different analysis sets
Publications / Cases True (+/−); False (+/−) Accuracy% Se% Sp% PPV% NPV% Rho (95%CI)
Primary analysis seta 25 / 44 (3/8); (0/0) 100 100 100 100 100 82 (43 to 95%)
All case reportsb 38 / 56 (3/8); (0/0) 100 100 100 100 100 83 (47 to 96%)
Analyzed in Bradley study excludedc 22 / 33 (3/8); (0/0) 100 100 100 100 100 82 (43 to 95%)
Excluding congress communicationsd 21 / 36 (2/8); (0/1e) 91 67 100 100 89 82 (43 to 95%)
Legend: aAll case reports of male MPS-II treated with ERT report efficacy and safety. These cases reports were written in a narrative form (results not aggregated).
They were published prior to Bradley bibliographic search
6MWT 6-min walk test, CI Confidence interval, NPV Negative predictive value, PPV Positive predictive value, Rho Spearman correlation coefficient, Se Sensitivity,
Sp Specificity.
bAll case reports of male MPS-II treated with ERT report efficacy and safety, despite being published after the bibliographic search for Bradley (31 December 2015)
cAll case reports included in the primary analysis set, excluding all studies also analyzed in the Bradley study
dAll case reports included in the primary analysis set, excluding all congress communications
eDevelopment of antibodies was an outcome that did not show a significant modification, although it was classified as high to moderate SOE in the
Bradley study.
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classified as acceptable evidence by the strong method in
our analysis.
Regarding IRRs, which our analysis categorized as un-
acceptable evidence, we only considered as relevant the
IRRs that caused ERT dose changes. Data from the HOS
registry showed that although 32% of patients suffer
from IRRs, most patients (85%) experience them during
the first 3 months of treatment and most IRRs are mild
or moderate in severity and can be managed without
interrupting treatment [38].
An important point to consider is the futility boundary
selected in our analysis (null hypothesis). The objective
of Bradley et al. [12] and their meta-analyses was to
identify benefits and harms of ERT, with the study de-
fined as a pilot. There was not a criterion for clinical
meaningfully effect. Therefore, the objective of the meta-
analysis was similar to phase II designs, in which it is
intended to explore the benefits and harms of a specific
treatment. In accordance with previous publications
evaluating treatment activity in phase II trials [41], a per-
centage of patients equal or lower than 5% showing a re-
sponse has been considered as the null hypothesis.
Accordingly, we observed that the best agreement with
clinical study meta-analysis results were observed with
the preplanned limit of no effect of 5%, which agrees
with previous recommendations in designs with the
same purpose [41]. Case report meta-analyses with other
purposes, e.g., identifying effects higher than an active
comparator, may require the null hypothesis to be based
on historical control estimations.
We have demonstrated that standardization and a good
definition of outcomes evaluated in case reports are
strongly related with the validity of the results obtained
based on their aggregation [8]. Thus, excluding results
from poorly defined outcomes is a useful criterion to con-
trol the quality of single cases in a case report meta-
analysis, as required in any meta-analysis [13].
Different authors have underlined the impact of clin-
ical report results in clinical practice and research [1],
while clinical cases have traditionally been of great im-
portance in determining patient treatment in the context
of rare diseases [7]. Our study suggests that the combin-
ation of these single cases can lead to robust results. Pre-
vious experience in a personalized medical context
suggests that understanding the biologic mechanism of
disease is more critical for treatment success in pivotal
studies than a simple demonstration of superiority in a
randomized-controlled study [39, 42].
Clinical reports have a high risk of publication bias [6]
and it is expected that only positive results will be pub-
lished. As a conservative assumption, we considered all
outcomes not reported in a case study to not have im-
proved. However, this assumption cannot prevent bias
related to unpublished cases. Based on this issue, an
alternative explanation of study results is that case re-
ports confirming clinical study conclusions have a higher
probability of being accepted and published in a journal.
However, this does not explain that the level of agree-
ment of case reports and clinical study meta-analyses re-
sults was higher, selecting only standardized and well-
defined outcomes.
Another important limitation is that we cannot esti-
mate the effect size of an outcome. Nevertheless, we ob-
served that most clinical cases do not report enough
information to aggregate study results in a mean, me-
dian, or a proportion with a confidence interval. This
highlights the importance of initiatives to homogenize
and upgrade the quality of the information published in
case reports [9]. Additionally, we did not analyze the ef-
fect of ERT, taking into account the different treatment
doses used in case reports, since we intend to compare
our results with those of Bradley et al. [12], who they did
not report this subgroup analysis. Either way, most cases
evaluated in both studies were treated with a standard
dose (0.5 mg/kg/weekly).
This analysis was confirmed in a MPS-II population
treated with ERT, with results explored in a specific
group of MPS-I patients. New studies must assess if re-
sults can be generalized for other diseases and patient
profiles.
A meta-analysis of clinical reports cannot replace
evidence provided by clinical trials. Subject recruit-
ment in rare diseases and personalized medicine rep-
resent a critical task in clinical research [2, 43, 44]. In
a therapeutic context, in which most studies become
clinical reports, excluding them from systematic re-
view increases the risk of bias and reduces efficiency,
as all available evidence is not considered [45]. There
is evidence that case reports translate useful data col-
lection in cases of rare phenomena, and contribute to
the progress and dissemination of novel scientific dis-
coveries three or more years earlier than clinical stud-
ies [11]. In this period, daily clinical practice or the
design of confirmatory clinical trials require evidence
from published clinical reports [8].
Conclusions
We demonstrated the agreement between the results
from case reports and clinical studies based on meta-
analyses, which evaluate efficacy and safety of enzyme
replacement therapy in patients with MPS-II. These
results confirm previous results observed in MPS-I
adult patients.
We suggest that quantitatively combining results from
case reports with standardized and well-defined out-
comes, rather than analyzing them separately or qualita-
tively, may improve clinical evidence of the effect of a
therapeutic strategy.
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Additionally, we have proposed some methods to
evaluate publication bias and heterogeneity of the in-
cluded studies in a meta-analysis of case reports.
Case reports meta-analyses might help improving the
clinical practice and the design of clinical trials in the
context of rare diseases and increasingly in other areas
of personalized medicine.
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